SGLT2 Inhibition Changing What Fuels the Heart

被引：15
作者：
Lehrke, Michael [1 ]
机构：
[1] Univ Hosp RWTH Aachen, Dept Internal Med 1, Aachen, Germany
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 15期
关键词：
animal models; cardiac remodeling; diabetes; heart failure; myocardial metabolism; SGLT2; inhibition; TYPE-2; DIABETES-MELLITUS; EMPAGLIFLOZIN; OUTCOMES;
D O I：
10.1016/j.jacc.2019.02.023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1945 / 1947
页数：3
相关论文
共 17 条
[1]   The Failing Heart Relies on Ketone Bodies as a Fuel (vol 133, pg 698, 2016) [J].
Aubert .
CIRCULATION, 2018, 138 (15) :E422-E422
[2]   The Failing Heart Relies on Ketone Bodies as a Fuel [J].
Aubert, Gregory ;
Martin, Ola J. ;
Horton, Julie L. ;
Lai, Ling ;
Vega, Rick B. ;
Leone, Teresa C. ;
Koves, Timothy ;
Gardell, Stephen J. ;
Krueger, Marcus ;
Hoppel, Charles L. ;
Lewandowski, E. Douglas ;
Crawford, Peter A. ;
Muoio, Deborah M. ;
Kelly, Daniel P. .
CIRCULATION, 2016, 133 (08) :698-705
[3]   Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials [J].
Boussageon, Remy ;
Bejan-Angoulvant, Theodora ;
Saadatian-Elahi, Mitra ;
Lafont, Sandrine ;
Bergeonneau, Claire ;
Kassai, Behrouz ;
Erpeldinger, Sylvie ;
Wright, James M. ;
Gueyffier, Francois ;
Cornu, Catherine .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[4]   Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Maione, Maria ;
Lai, Vesta ;
Lee, Alana ;
Fagan, Nora M. ;
Woerle, Hans J. ;
Johansen, Odd Erik ;
Broedl, Uli C. ;
von Eynatten, Maximilian .
CIRCULATION, 2014, 129 (05) :587-597
[5]   CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis [J].
Ferrannini, Ele ;
Mark, Michael ;
Mayoux, Eric .
DIABETES CARE, 2016, 39 (07) :1108-1114
[6]   Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial [J].
Inzucchi, Silvio E. ;
Iliev, Hristo ;
Pfarr, Egon ;
Zinman, Bernard .
DIABETES CARE, 2018, 41 (01) :E4-E5
[7]   Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease [J].
Kappel, Ben A. ;
Lehrke, Michael ;
Schutt, Katharina ;
Artati, Anna ;
Adamski, Jerzy ;
Lebherz, Corinna ;
Marx, Nikolaus .
CIRCULATION, 2017, 136 (10) :969-972
[8]   Regulation of protein synthesis by branched-chain amino acids [J].
Kimball, SR ;
Jefferson, LS .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2001, 4 (01) :39-43
[9]   Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].
Neal, Bruce ;
Perkovic, Vlado ;
Mahaffey, Kenneth W. ;
de Zeeuw, Dick ;
Fulcher, Greg ;
Erondu, Ngozi ;
Shaw, Wayne ;
Law, Gordon ;
Desai, Mehul ;
Matthews, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657
[10]   Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics [J].
Santos-Gallego, Carlos G. ;
Antonio Requena-Ibanez, Juan ;
San Antonio, Rodolfo ;
Ishikawa, Kiyotake ;
Watanabe, Shin ;
Picatoste, Belen ;
Flores, Eduardo ;
Garcia-Ropero, Alvaro ;
Sanz, Javier ;
Hajjar, Roger J. ;
Fuster, Valentin ;
Badimon, Juan J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (15) :1931-1944
12